Sanofi, Novo Spar In Insulin Pen Patent Suit—Again
Sanofi-Aventis has bulwarked its defenses against Novo Nordisk A/S and stepped up its demands for relief in their insulin pen spat with a dozen counterclaims, citing a licensing deal it said...To view the full article, register now.
Already a subscriber? Click here to view full article